Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — House Democrats are expected to insert a controversial Medicaid drug pricing policy into a fast-moving Covid-19 relief bill, several health care lobbyists and a congressional aide briefed on the package told STAT.

The policy aims to help states recoup some of the costs they incur in their Medicaid programs when drug makers hike the prices of certain drugs. Right now, federal law caps how much states can collect. Congress’ new policy would rescind that so-called “Medicaid rebate cap.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I am a little confused by the math used in the “example” in the story – are you saying that they can base a demanded discount to the Medicaid price based on what is happening over in the private insurance pricing for the same drug, and demand a rebate equal to the commercial rebate in $ which actually exceeds the contracted Medicaid price? The key to fixing the problem for our entire society (not just government plans) is to outlaw rebates and require all payer pricing for Rx from the original manufacturers with value added transparency between that price and the ultimate purchaser. But, thanks for this insight on the bill!

Comments are closed.